In a 5‑month pregnant woman, is it safe to prescribe Budecort (budesonide) inhaler, Duolin nebulizer (ipratropium + albuterol), and Montek LC (montelukast + levocetirizine) tablet?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, you can safely prescribe all three medications to a 5-month pregnant woman with asthma

Based on established international guidelines and safety data, Budecort (budesonide inhaler), Duolin nebulizer (ipratropium + albuterol), and Montek LC (montelukast + levocetirizine) are acceptable for use during pregnancy, with budesonide and albuterol being the preferred agents in their respective classes. 1, 2

Budecort (Budesonide Inhaler) - PREFERRED AGENT

Budesonide is the preferred inhaled corticosteroid during pregnancy due to the most extensive safety data available 2. The 2020 ERS/TSANZ guidelines classify budesonide as Category A (TGA) and Category B (FDA), indicating reassuring human and animal data 1. Multiple studies confirm no increased risk of major malformations, intrauterine growth restriction, preterm delivery, or low birth weight at usual doses 1.

Key point: The NAEPP guidelines explicitly state that "it is safer for pregnant women with asthma to be treated with asthma medications than for them to have asthma symptoms and exacerbations" 2. Inadequate asthma control poses greater fetal risk than the medications themselves.

Duolin Nebulizer (Ipratropium + Albuterol) - SAFE COMBINATION

Albuterol Component - PREFERRED SHORT-ACTING BETA-AGONIST

Albuterol is the preferred short-acting bronchodilator during pregnancy with an excellent safety profile and the most extensive pregnancy data of any available beta-agonist 2. A 1988 prospective study of 259 pregnant women using inhaled beta-agonists found no significant differences in perinatal mortality, congenital malformations, preterm births, low birth weight, or Apgar scores compared to controls 3.

Ipratropium Component - ACCEPTABLE

The 2020 guidelines note that ipratropium has minimal experience during pregnancy but animal studies show no teratogenic effects 1. The NAEPP guidelines include ipratropium in their dosing recommendations for acute exacerbations during pregnancy, indicating acceptance of its use 2.

Montek LC (Montelukast + Levocetirizine) - ACCEPTABLE WITH CAVEATS

Montelukast Component - ALTERNATIVE AGENT

Montelukast is classified as Category B1 (TGA) and Category B (FDA) 1. While guidelines list it as an alternative rather than preferred therapy compared to inhaled corticosteroids 2, recent high-quality evidence is reassuring:

  • A 2026 US population-based cohort study of 44,435 pregnancies found no increased risk of major congenital malformations with first-trimester montelukast exposure 4
  • A 2022 Japanese prospective cohort study of 231 pregnancies showed no association with major congenital anomalies (adjusted OR 0.78,95% CI 0.23-2.05) 5
  • A 2009 multicentre study of 180 montelukast-exposed pregnancies reported only 1 major malformation among 160 live births 6

Important caveat: One study noted a potential signal for cleft palate/lip with montelukast + ICS combination, though events were limited (<5 cases) 4. This requires further confirmation but should not preclude use given the overall safety profile.

Levocetirizine Component - ACCEPTABLE SECOND-GENERATION ANTIHISTAMINE

While the guidelines specifically mention cetirizine and loratadine as preferred second-generation antihistamines during pregnancy 7, levocetirizine (the active enantiomer of cetirizine) shares a similar safety profile. Second-generation antihistamines are generally considered safe during pregnancy, with preference over first-generation agents.

Clinical Algorithm for Use

For this 5-month pregnant patient:

  1. Continue Budecort - This is the gold standard inhaled corticosteroid for pregnancy
  2. Use Duolin as needed - Both components are safe; albuterol is the preferred bronchodilator
  3. Continue Montek LC if already controlling symptoms - The NAEPP specifically states that leukotriene receptor antagonists are acceptable for pregnant women whose asthma was successfully controlled with this medication prior to pregnancy 2

Critical consideration: If the patient was NOT on montelukast before pregnancy and asthma is not well-controlled, consider switching to budesonide monotherapy or adding a long-acting beta-agonist to budesonide rather than starting montelukast, as inhaled corticosteroids are more effective 2.

Important Monitoring Points

  • Avoid grapefruit/grapefruit juice with budesonide as it increases blood levels 8
  • Monitor for signs of adrenal suppression with prolonged high-dose inhaled corticosteroid use 8
  • Ensure proper asthma control to maintain maternal oxygenation and fetal oxygen supply 2
  • Serial ultrasounds starting at 32 weeks may be considered for suboptimally controlled asthma 2

The benefit of maintaining asthma control far outweighs any theoretical medication risks during pregnancy. Uncontrolled asthma poses documented risks of preeclampsia, preterm delivery, low birth weight, and perinatal mortality 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.